[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-neoplasm":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,101,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100552714","novel-bipolar-radiofrequency-ablation-knife-in-esophageal-lesions-100552714",false,"NCT06476678","Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions","Prospective Multicenter Trial Evaluating the Efficacy and Feasibility of a Novel Bipolar Radiofrequency Ablation Knife in Esophageal Endoscopic Submucosal Dissection","Inclusion Criteria:\n\n* Patient is \\>18 years of age\n* Patient can provide informed consent\n* Patient is referred for resection of precancerous lesions meeting the following criteria:\n\n  * Mucosal based polyp\n  * Located gastroesophageal junction (GEJ) or proximal to GEJ\n  * No previous endoscopic resection attempted (EMR or ESD)\n\nExclusion Criteria:\n\n* Patients with International Normalized Ratio (INR) \\>1.5 or Platelets \\\u003C50,000\n* Lesions extending past GEJ\n* Subepithelial lesions","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","Both Baylor St Luke's Medical Center and Mayo Scottsdale are considered endoscopic submucosal dissection (ESD) centers of excellence. The investigators at Baylor College of Medicine have previously reported our Esophageal ESD experience using the monopolar current knife. Moreover, the research team have previously reported on the clinical efficacy of the bipolar RFA knife during per-oral endoscopic myotomy (POEM) and colonic ESD. The goal of our study is to prospectively evaluate the efficacy, safety and feasibility of Esophageal ESD using a novel Bipolar-Current ESD device.",[24,25,26,27],"Esophageal Neoplasm","Esophageal Polyp","Endoscopic Submucosal Dissection","Bipolar Electrocautery","RECRUITING","2026-03-23",{"date":31,"type":32},"2026-03-25","ACTUAL",{"date":34,"type":32},"2024-10-15",{"date":36,"type":20},"2027-12-31",{"name":38,"class":39},"Baylor College of Medicine","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":50,"type":20},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,24,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":93,"type":32},"2026-03-05",{"date":95,"type":32},"2019-02-01",{"date":97,"type":20},"2030-08-01",{"name":99,"class":39},"UMC Utrecht",18,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100079306","genetic-determinants-of-barretts-esophagus-and-esophageal-adenocarcinoma-100079306","NCT00288119","Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma","Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma","FBE","Eligible cases will be defined as those patients and their family members who meet the following criteria:\n\n* Barrett's esophagus confirmed by review of pathology and endoscopy report or adenocarcinoma of the esophagus or family members of person with Barrett's esophagus or adenocarcinoma of the esophagus.\n* Male or female age 18 or older at time of enrollment or male or female less than 18 years of age at time of enrollment with parental consent.\n* Ability to give informed consent, if patient is age 18 or older.",true,{"count":111,"type":20},2000,"The overall objectives of this BETRNet Research Center (RC) are:\n\n1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA)\n2. to increase the biological understanding of key observations made by our clinical researchers;\n3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC;\n4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC;\n5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.",[114,24],"Barrett's Esophagus",[114],"2025-07-16",{"date":118,"type":32},"2025-07-18",{"date":120,"type":32},"2005-10-01",{"date":122,"type":20},"2028-07-31",{"name":124,"class":39},"Case Western Reserve University",10,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":40},"100553081","definitive-radiotherapy-for-cervical-and-upper-thoracic-esophageal-cancer-chcues-a-multi-center-real-world-study-100553081","NCT06481449","Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study","Inclusion Criteria:\n\n1. Age 18 and older.\n2. Confirmation of esophageal cancer through histopathology or cytology.\n3. Primary tumor location within the cervical or upper thoracic segment, extending from the upper esophageal sphincter to the azygos vein.\n4. Absence of distant metastasis.\n5. Patients unable or unwilling to undergo surgical treatment for various reasons.\n6. Receipt of radical radiotherapy as the first-line treatment, with or without chemotherapy, immunotherapy, or targeted therapy.\n7. Undergoing conventional radiation therapy (1.8-2.0Gy per session, once per day).\n8. Receiving 3DCRT or IMRT radiotherapy.\n9. Availability of complete radiotherapy prescription dose information and follow-up records.\n\nExclusion Criteria:\n\n1. Receipt of radiation dose below 50Gy.\n2. History of other malignancies (except for cured cancer in situ and malignancies cured for over 5 years) or laryngeal invasion.\n3. Diagnosis of double primary esophageal cancer.\n4. Prior chest radiation therapy within the past 5 years.\n5. Recurrent or metastatic esophageal cancer.\n6. Receipt of 2D radiotherapy, large fractionation, or hyper-fractionation radiotherapy.\n7. Patients with incomplete radiotherapy dose and follow-up data.",{"count":133,"type":20},2600,"Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC\\&UES) explores radical radio(chemo)therapy efficacy and safety",[24],"2024-06-27",{"date":138,"type":32},"2024-07-01",{"date":140,"type":32},"2000-01-01",{"date":142,"type":20},"2024-12-01",{"name":144,"class":39},"Hebei Medical University Fourth Hospital"]